// App-Quantinova.ai

OP0027 (2022) : ASSOCIATION BETWEEN BASELINE CARDIOVASCULAR RISK AND INCIDENCE RATES OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND MALIGNANCIES IN PATIENTS WITH PSORIATIC ARTHRITIS AND PSORIASIS RECEIVING TOFACITINIB

Researchers

Presenter

  • L. E. Kristensen

Principal Investigators

  • B. Strober

  • D. Poddubnyy

  • Y. Y. Leung

  • H. Jo

  • K. Kwok

  • I. Vranic

  • D. Fleishaker

  • L. Fallon

  • A. Yndestad

  • D. D. Gladman

Medical Centers

  • Copenhagen University Hospital, Bispebjerg and Frederiksberg, The Parker Institute, Copenhagen, Denmark

  • Central Connecticut Dermatology Research, Cromwell, CT, United States of America

  • Yale University, Department of Dermatology, New Haven, CT, United States of America

  • Charité-Universitätsmedizin, Gastroenterology, Infectious Diseases and Rheumatology, Berlin, Germany

  • German Rheumatism Research Centre, Berlin, Germany

  • Singapore General Hospital, Department of Haematology, Singapore, Singapore

  • Duke-NUS Medical School, Clinical Sciences Department, Singapore, Singapore

  • Pfizer Inc, Inflammation and Immunology, Peapack, NJ, United States of America

  • Pfizer Inc, Inflammation and Immunology, Peapack, NJ, United States of America

  • Pfizer Ltd, Inflammation and Immunology, Tadworth, Surrey, United Kingdom

  • Pfizer Inc, Inflammation and Immunology, Kirkland, QC, Canada

  • Pfizer Inc, Inflammation and Immunology, Oslo, Norway

  • University of Toronto, Professor of Medicine, Toronto, ON, Canada

  • Toronto Western Hospital, Schroeder Arthritis Institute, Krembil Research Institute, Toronto, Canada

Locations

  • Denmark

  • United States

  • Germany

  • Singapore

  • United Kingdom

  • Canada

  • Norway

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Musculoskeletal

  • Dermatology

  • Cardiovascular (CVS)

  • Oncology (ONC)

Disease

  • Coronary Artery Disease

  • Myocardial infarction

  • Psoriatic arthritis

  • Angina

  • Hypertension

  • Skin carcinoma

  • Inflammatory Arthritis

  • Psoriasis

  • Melanoma

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Tasocitinib

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • Pfizer

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved